| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:PROTEIN C
CAS:42617-41-4
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:ProteinC
CAS:42617-41-4
Purity:>=90% (SDS-PAGE) Package:0.1mg Remarks:P2200
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
| Products Intro: |
Product Name:Protein C from human plasma Activated, lyophilized powder, >=90% (SDS-PAGE)
CAS:42617-41-4
Purity:Activated, lyophilized powder, ≥90% (SDS-PAGE) Package:0.1mg Remarks:NULL
|
|
| | PROTEIN C Basic information |
| Product Name: | PROTEIN C | | Synonyms: | PROTEIN C, ACTIVATED, HUMAN;PROTEIN C;PROTEIN C, ACTIVATED;PROTEIN C, HUMAN PLASMA;PROTEIN C CONTROL PLASMA;PROTEIN C, HUMAN;PROTEIN C, ACTIVATED, HUMAN PLASMA;HUMAN PROTEIN C | | CAS: | 42617-41-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![PROTEIN C Structure]() |
| | PROTEIN C Chemical Properties |
| storage temp. | -20°C | | solubility | H2O: 1 mg/mL | | form | lyophilized powder |
| | PROTEIN C Usage And Synthesis |
| Description | Drotrecogin alfa was introduced in the US as a new intravenous treatment for the
reduction of mortality in adult patients with severe sepsis associated with acute organ
dysfunction. Drotrecogin aifa is the first recombinant activated protein C expressed in
human kidney 293 cells. Activated protein C1 an endogenous serine protease, acts as an
antithrombotic via inhibition of factor Va and Vllla, promotes fibrinolysis via inactivation of
plasminogen-activator inhibitor-1 and exerts an anti-inflammatory effect by inhibiting the
production of inflammatory cytokines (tumor necrosis factor-alpha, interieukin-1 and 6) by
monocytes. It was shown that the majority of patients with sepsis have reduced levels of
activated protein C. In a baboon model of lethal E. coli sepsis, administration of activated
protein C reduced mortality. In a phase III clinical trial, intravenous infusion of drotrecogin
alfa at a dose of 24 μg/kg/h over 96 h significantly reduced the risk of death compared with
placebo in patients with severe sepsis. However, an increased risk of serious bleeding has
been associated with the administration of the drug. | | Originator | Lilly (US) | | Uses | Protein C from human plasma has been used for pre-treatment of endothelial cells prior to antibody-inhibition assay. It has also been used in activated protein C (APC) assay to determine its inhibitory effect on copper. | | Brand name | Xigris | | General Description | Protein C from human plasma is encoded by the gene PROC. In human chromosome, the gene is localised on chromosome 2q14. Activated protein C (APC) cleaves protease activated receptor 1 (PAR1) resulting in cytoprotective and anti-inflammatory effects. Clinical trials with APC implicates its use in treating severe early onset preeclampsia in pregnant women and prolongs pregnancy and helps in perinatal outcomes. | | Biochem/physiol Actions | Adenomatous Polyposis Coli (APC) has a key role in the proteasome-mediated degradation of β-catenin. APC mutations cause accumulation of β-catenin in the nucleus leading to activation of LEF-1 and/or TCF, and the induction of target genes such as the oncogene c-myc. It is involved in regulation of mitotic chromosome separation and stability. |
| | PROTEIN C Preparation Products And Raw materials |
|